Our results indicate that the production of itaconate in tumors stimulated by thimerosal is sufficient to elicit tumor immunogenicity, yet may not elicit immune suppression within the tumor microenvironment due to its limited secretion into the extracellular space from tumor cells, possibly attributed to the low expression of the itaconate exporter ABCG2 (Chen et al, 2024) (Appendix Fig. S10A). This evidence concerns the gene ABCG2 and neoplasm.